Tag Archives: drugs

King of Boys

Award winning Nigerian movie “King of Boys” (2018) directed by Kemi Adetiba and starring Sola Sobowale, Adesua Etomi and Paul Sambo among others.

Its a Nigerian crime fiction drawn on the style of Godfather and so many of crime thrillers but this has a godmother instead. Alhaja Eniola Salami (Sola Sobowale) is controlling the crime and drugs in Lagos with separate factions under her. She has inherited from her husband as have others from their family members controlling drugs and kidnappings, theft, robbery etc.

But because of her overpowering dominance, it has ruffled feathers amongst many including the politicians, other gang lords etc. What travails she goes through and how she comes out on top with so many tragedies facing her forms the rest of the story.

Its a long movie, almost 3 hours, so gets slow in the middle. But Kemi has built up the story quite well with Paul Sambo doing the role of the honest cop Nurudeen Gobir. Adesua Etomi as Kemi Salami the daughter of Eniola oozes sexuality and arrogance in her role.

There are whole lot of vested interests involved and there are too many players spoiling the pie so to speak. Typical of what is happening in most countries with crime, drugs, politics mixing to form a heady mix of deadly cocktail of danger. Sola Sobowale has done a brilliant role as the Godmother, incidentally she is called as King in the movie.

You can watch the movie here.

Leave a comment

Filed under cinema

production linked incentive for pharma sector


The Union Cabinet, chaired by the Prime Minister, Shri Narendra Modi has approved Production Linked Incentive (PLI) Scheme for Pharmaceuticals over a period of Financial Year 2020-21 to 2028-29.

The Scheme will benefit domestic manufacturers, help in creating employment and is expected to contribute to the availability of wider range of affordable medicines for consumers.

The scheme is expected to promote the production of high value products in the country and increase the value addition in exports.  Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.

The scheme is expected to generate employment for both skilled and un-skilled personnel, estimated at 20,000 direct and 80,000 indirect jobs as a result of growth in the sector.

It is expected to promote innovation for development of complex and high-tech products including products of emerging therapies and in-vitro Diagnostic Devices as also self-reliance in important drugs.  It is also expected to improve accessibility and affordability of medical products including orphan drugs to the Indian population.  The Scheme is also expected to bring in investment of Rs.15,000 crore in the pharmaceutical sector.

The scheme will be part of the umbrella scheme for the Development of Pharmaceutical Industry. The objective of the scheme is to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector. One of the further objectives of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.

The salient features of the Scheme are as follows:-

Target Groups:

The manufacturers of pharmaceutical goods registered in India will be grouped based on their Global Manufacturing Revenue (GMR) to ensure wider applicability of the scheme across the pharmaceutical industry and at the same time meetthe objectives of the scheme. The qualifying criteria for the three groups of applicants will be as follows-

(a) Group A: Applicants having Global Manufacturing Revenue (FY 2019-20) of pharmaceutical goods more than or equal to Rs 5,000 crore.

(b) Group B: Applicants having Global Manufacturing Revenue (FY 2019-20) of pharmaceutical goods between Rs 500 (inclusive) crore and Rs 5,000 crore.

(c) Group C: Applicants having Global Manufacturing Revenue (FY 2019-20) of pharmaceutical goods less than Rs 500 crore. A sub-group for MSME industry will be made within this group, given their specific challenges and circumstances.

Quantum of Incentive:

The total quantum of incentive (inclusive of administrative expenditure) under the scheme is about Rs 15,000 crore. The incentive allocation among the Target Groups is as follows:

(a)          Group A: Rs 11,000 crore.

(b)          Group B: Rs 2,250 crore.

(c)           Group C: Rs 1,750 crore.

The incentive allocation for Group A and Group C applicants shall not be moved to any-other category. However, incentive allocated to Group B applicants, if left underutilized can be moved to Group A applicants.

Financial Year 2019-20 shall be treated as the base year for computation of incremental sales of manufactured goods.

Category of Goods:

The scheme shall cover pharmaceutical goods under three  categories as mentioned below:

  1. Category 1

Biopharmaceuticals; Complex generic drugs; Patented drugs or drugs nearing patent expiry; Cell based or gene therapy drugs; Orphan drugs; Special emptycapsules like HPMC, Pullulan, enteric etc.; Complex excipients; Phyto-pharmaceuticals: Otherdrugs as approved.

(b)Category 2

Active Pharmaceutical Ingredients / Key Starting Materials / Drug Intermediates.

(c)Category 3 (Drugs not covered under Category 1 and Category 2)

Repurposed drugs; Auto immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs; In vitro diagnostic devices; Other drugs as approved; Other drugs not manufactured in India.

Rate of incentive will be 10% (of incremental sales value) for Category 1 and Category 2 products for first four years, 8% for the fifth year and 6% for the sixth year of production under the scheme.

Rate of incentive will be 5% (of incremental sales value) for Category 3 products for first four years, 4% for the fifth year and 3% for the sixth year of production under the scheme.

The duration of the scheme will be from FY 2020-21 to FY 2028-29. This will include the period for processing of applications (FY 2020-21), optional gestation period of one year (FY 2021-22), incentive for 6 years and FY 2028-29 for disbursal of incentive for sales of FY 2027-28.


Indian pharmaceutical industry is 3rd largest in the world by volume and is worth USD 40 billion in terms of value. The country contributes 3.5% of total drugs and medicines exported globally. India exports pharmaceuticals to more than 200 countries and territories including highly regulated markets such as USA, UK, European Union, Canada etc. India has a complete ecosystem for the development and manufacturing of pharmaceuticals with companies having state of the art facilities and highly skilled/technical manpower. The country also has a number of renowned pharmaceutical educational and research institutes and a robust support of allied industries.

At present, low value generic drugs account for the major component of Indian exports, while a large proportion of the domestic demand for patented drugs is met through imports. This is because the Indian Pharmaceutical sector lacks in high value production along with the necessary pharma R&D. In order to incentivize the global and domestic players to enhance investment and production in diversified product categories, a well-designed and suitably targeted intervention is required to incentivise specific high value goods such as bio-pharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry and cell based or gene therapy products etc.

Leave a comment

Filed under Uncategorized

CSR – covid drugs

MCA has vide its notification dated 24th August, 2020 amended Schedule VII of the Companies Act, 2013 to include the following .

The amendment has been carried out in Rule 2(1)(e) – the rule presently reads as under:

e) “CSR Policy” relates to the activities to be undertaken by the 3[company in areas or subjects] specified in Schedule VII to the Act and the expenditure thereon, excluding activities undertaken in pursuance of normal course of business of a company;

Now vide this amendment, a proviso has been added to this rule, as follows:

“Provided that any company engaged in research and development activity of new vaccine, drugs and medical devices in their normal course of business may undertake research and development activity of new vaccine, drugs and medical devices related to COVID-19 for financial years 2020-21, 2021-22 and 2022-23 subject to the conditions that-
(i) such research and development activities shall be carried out in collaboration with any of the institutes or organisations mentioned in item (ix) of Schedule VII to the Act.
(ii) details of such activity shall be disclosed separately in the Annual Report on CSR included in the Board’s Report”.

So basically companies in pharma business undertaking research and development into covid drugs, trials etc. can take that expenditure as CSR expenditure provided they are collaborating with one of the institutes or organisations mentioned in item (ix) of the said schedule. And details of such activity has to be disclosed separately in the annual report in the item on CSR.

These institutes are : public funded Universities, Indian Institute of Technology (IITs), National Laboratories and Autonomous Bodies (established under the auspices of Indian Council of Agricultural Research (ICAR), Indian Council of Medical Research (ICMR), Council of Scientific and Industrial Research (CSIR), Department of Atomic Energy (DAE), Defence Research and Development Organisation (DRDO), [Department of Biotechnology (DBT)], Department of Science and Technology (DST), Ministry of Electronics and Information Technology).

Leave a comment

Filed under company law

La Vendedora de Rosas

La Vendedora de Rosas or The Rose Seller, a brutal Columbian movie by Victor Gaviria. Loosely based on a story by Hans Christian Anderson it depicts the lives of young girls in a crime infested, drug infested suburb of Columbia. Children who run away from their homes because of violence in their homes get caught into the drug gangs racket, sniffing glue and trying to eke a living in a violent poverty ridden world. Monica is the fulcrum of the story, brilliantly played by Leidy Tabares, she is the one around whom the other girls revolve a sort of an unofficial leader of them. In comes Andrea all of 10 years old, also run away from a violent home. The girls have to be smart to survive in this squalid world where young boys are constantly looking to take advantage of them. All of them have one soft spot, for Monica it is her dead grandmother whom she had loved very much. A sort of Salaam Bombay kinda movie it delves into a Columbian life where violence is a just a few seconds away. A lot of scenes in the movie is quite realistic. Gaviria has managed to extract quite brilliant performances from all the kids in the movie.  

Leave a comment

Filed under cinema